NASDAQ:CMMB

Chemomab Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy CMMB

*Your capital is at risk

$1.72

-0.0200 (-1.15%)

At Close: Jun 03, 2026

Chemomab Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 100.00. In total, the insiders bought 1.33M and sold 751.86K CMMB shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	100.00
● Buy	1.33M shares
● Sell	751.86K shares
90% Buy Activity Negligible or No Correlation
No Significant Signals No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date	Type	Person	Role	Amount
Mar 18, 2026 Buy	Stock option (right to buy American Depositary Shares)	Moses Alan Charles Director	Director	1 705 Value: $24.1K
Mar 18, 2026 Buy	Stock option (right to buy American Depositary Shares)	Moses Alan Charles Director	Director	2 971 Value: $324.0K
Mar 18, 2026 Buy	Stock option (right to buy American Depositary Shares)	Cohen Neil Harris Director	Director	3 821 Value: $23.5K
Mar 18, 2026 Buy	Stock option (right to buy American Depositary Shares)	Cohen Neil Harris Director	Director	2 520 Value: $7K
Mar 18, 2026 Buy	Stock option (right to buy American Depositary Shares)	Cohen Neil Harris Director	Director	1 714 Value: $11.1K
Mar 18, 2026 Buy	Stock option (right to buy American Depositary Shares)	Cohen Neil Harris Director	Director	1 705 Value: $24.1K
Mar 18, 2026 Buy	Stock option (right to buy American Depositary Shares)	Cohen Neil Harris Director	Director	172 Value: $9K
Mar 18, 2026 Buy	Stock option (right to buy American Depositary Shares)	Cohen Neil Harris Director	Director	2 971 Value: $324.0K
Mar 18, 2026 Buy	American Depositary Shares	Cohen Neil Harris Director	Director	0 Value: $0
Mar 18, 2026 Buy	Stock option (right to buy American Depositary Shares)	Darvish Nissim Director	Director	4 221 Value: $14.5K
Mar 18, 2026 Buy	Stock option (right to buy American Depositary Shares)	Darvish Nissim Director	Director	5 143 Value: $35.0K
Mar 18, 2026 Buy	Stock option (right to buy American Depositary Shares)	Darvish Nissim Director	Director	1 714 Value: $11.1K
Mar 18, 2026 Buy	Stock option (right to buy American Depositary Shares)	Darvish Nissim Director	Director	1 705 Value: $24.1K
Mar 18, 2026 Buy	Stock option (right to buy American Depositary Shares)	Darvish Nissim Director	Director	2 971 Value: $324.0K
Mar 18, 2026 Buy	Stock option (right to buy American Depositary Shares)	Darvish Nissim Director	Director	2 531 Value: $8K
Mar 18, 2026 Buy	American Depositary Shares	Darvish Nissim Director	Director	0 Value: $0
Mar 18, 2026 Buy	Stock option (right to buy American Depositary Shares)	Mor George Adi Chief Executive Officer	CEO / President	8 431 Value: $27.0K
Mar 18, 2026 Buy	Stock option (right to buy American Depositary Shares)	Mor George Adi Chief Executive Officer	CEO / President	109 718 Value: $566.1K
Mar 18, 2026 Buy	Stock option (right to buy American Depositary Shares)	Mor George Adi Chief Executive Officer	CEO / President	32 925 Value: $195.6K
Mar 18, 2026 Buy	American Depositary Shares	Mor George Adi Chief Executive Officer	CEO / President	0 Value: $0
Mar 18, 2026 Buy	American Depositary Shares	Mor George Adi Chief Executive Officer	CEO / President	0 Value: $0
Mar 18, 2026 Buy	American Depositary Shares	Mor George Adi Chief Executive Officer	CEO / President	0 Value: $0
Mar 18, 2026 Buy	American Depositary Shares	Mor George Adi Chief Executive Officer	CEO / President	0 Value: $0
Mar 18, 2026 Buy	Stock option (right to buy American Depositary Shares)	Nicaise Claude Director	Director	1 714 Value: $11.1K
Mar 18, 2026 Buy	Stock option (right to buy American Depositary Shares)	Nicaise Claude Director	Director	1 705 Value: $24.1K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT CHEMOMAB THERAPEUTICS LTD.

Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and cha...

Read Full Profile Here